top of page

picture of a chemistry laboratory

INVESTORS

Stock Exchange Releases

15 Sep. 2023 J. Molner AS Consolidated Unaudited Interim Report for the First 6 Months of 2023 and increase of The J. Molner Company OÜ voluntary reserve

6 Sep. 2023 J. Molner Signs Licensing Agreement for Five Approved Drugs in the US

2 Aug. 2023 Restructuring in the employee structure of the subsidiary of J.Molner AS The J. Molner Company OÜ

13 Jun. 2023 J. Molner submits drug application to U.S Food and Drug Administration (FDA)

Press Releases

7 Nov. 2022 Pharmaceutical company J. Molner raised about 700,000 euros in the IPO

27 Oct. 2022 J. Molner Introduction Webinar (English)

19 Oct. 2022 IPO of the pharmaceutical company Molner commences on 24 October

06 Oct. 2022 J. Molner submits first drug to Health Canada

Key Documents

Annual Meeting of Shareholders 2023

Notice of Annual Meeting (EE, EN)

Resolution of Management Board (EE)

Agenda of the Annual Meeting and Supervisory Board's recommendations (EE/EN)

Report of the Supervisory Board regarding financial year 2022 (EE/EN)

Power of Attorney Form (EE, EN)

Ballot and Instructions for Electronic Voting (EE, EN)

Annual Report for the Period 01.01.2022 - 31.12.2022

English Version (EN)

Estonian Version (EE)

Fireside Chat - 3 Nov 2022

live from the EBS studio, a conversation with our founder

Webinar - 27 Oct 2022

bottom of page